Independent educationNo sales. No dosing. Sources on every brief.

Source index · 71 unique records

Trace every conclusion to the record.

Browse the labels, regulatory pages, trials, human pharmacology, reviews, and preclinical studies used across reviewed briefs.

71Unique records
88Brief citations
20Connected briefs

71 unique records

Shared records are listed once with every connected brief.
01
Drug labelU.S. Food and Drug Administration · 2026Checked 2026-07-23

OZEMPIC (semaglutide) prescribing information, revised 05/2026

Open record
02
Drug labelU.S. Food and Drug Administration · 2025Checked 2026-07-23

RYBELSUS (semaglutide) prescribing information, revised 10/2025

Open record
03
Drug labelU.S. Food and Drug Administration · 2026Checked 2026-07-23

WEGOVY (semaglutide) prescribing information, revised 03/2026

Open record
06
RegulatoryU.S. Food and Drug Administration · 2026Checked 2026-07-23

Insulin: patient and product overview

Used byInsulin
Open record
07
Drug labelU.S. Food and Drug Administration · 2025Checked 2026-07-23

HUMALOG (insulin lispro) prescribing information

Used byInsulin
Open record
08
Randomized trialPubMed · New England Journal of Medicine · 1993Checked 2026-07-23

The effect of intensive treatment of diabetes on long-term complications in insulin-dependent diabetes mellitus

Used byInsulin
Open record
09
Randomized trialPubMed · Diabetes · 1997Checked 2026-07-23

Hypoglycemia in the Diabetes Control and Complications Trial

Used byInsulin
Open record
10
RegulatoryU.S. Food and Drug Administration · 2026Checked 2026-07-23

FDA approves the first rapid-acting insulin biosimilar product for diabetes

Used byInsulin
Open record
12
Drug labelU.S. Food and Drug Administration · 2026Checked 2026-07-23

MOUNJARO (tirzepatide) prescribing information

Open record
13
Drug labelU.S. Food and Drug Administration · 2026Checked 2026-07-23

ZEPBOUND (tirzepatide) prescribing information

Open record
14
Randomized trialPubMed · New England Journal of Medicine · 2022Checked 2026-07-23

Tirzepatide once weekly for the treatment of obesity

Open record
15
Randomized trialPubMed · New England Journal of Medicine · 2021Checked 2026-07-23

Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes

Open record
16
FDA reviewU.S. Food and Drug Administration · 2026Checked 2026-07-23

July 2026 PCAC briefing on BPC-157-related bulk drug substances

Used byBPC-157
Open record
18
Science reviewPubMed · Pharmaceutics · 2026Checked 2026-07-23

BPC-157 as an investigational peptide therapeutic: translational development barriers

Used byBPC-157
Open record
19
Human pilotPubMed · Alternative Therapies in Health and Medicine · 2025Checked 2026-07-23

Safety of intravenous infusion of BPC157 in humans: a pilot study

Used byBPC-157
Open record
20
PreclinicalPubMed · Journal of Applied Physiology · 2011Checked 2026-07-23

Promoting effect of BPC 157 on tendon healing: tendon outgrowth, cell survival, and migration

Used byBPC-157
Open record
21
Trial registryClinicalTrials.gov · 2026Checked 2026-07-23

BPC 157 for acute hamstring muscle strain repair

Used byBPC-157
Open record
22
Randomized trialPubMed · Journal of Clinical Endocrinology & Metabolism · 2006Checked 2026-07-23

Prolonged GH and IGF-1 stimulation by CJC-1295 in healthy adults

Used byCJC-1295
Open record
23
Human pharmacologyPubMed · Journal of Clinical Endocrinology & Metabolism · 2006Checked 2026-07-23

Pulsatile GH secretion during continuous stimulation by CJC-1295

Used byCJC-1295
Open record
24
FDA reviewU.S. Food and Drug Administration · 2024Checked 2026-07-23

CJC-1295 pharmacy compounding advisory review

Used byCJC-1295
Open record
25
Human pharmacologyPubMed · Pharmaceutical Research · 1999Checked 2026-07-23

Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers

Used byIpamorelin
Open record
26
Randomized trialPubMed · International Journal of Colorectal Disease · 2015Checked 2026-07-23

Randomized proof-of-concept study of ipamorelin for postoperative ileus

Used byIpamorelin
Open record
27
Drug labelU.S. Food and Drug Administration · 2024Checked 2026-07-23

VICTOZA (liraglutide) prescribing information

Open record
28
Drug labelU.S. Food and Drug Administration · 2026Checked 2026-07-23

SAXENDA (liraglutide) prescribing information

Open record
29
Randomized trialPubMed · New England Journal of Medicine · 2016Checked 2026-07-23

Liraglutide and cardiovascular outcomes in type 2 diabetes

Open record
30
Human pharmacologyPubMed · The Lancet · 2022Checked 2026-07-23

LY3437943 in people with type 2 diabetes: a phase 1b randomized trial

Open record
31
Randomized trialPubMed · The Lancet · 2023Checked 2026-07-23

Retatrutide for people with type 2 diabetes: a phase 2 randomized trial

Open record
32
Randomized trialPubMed · New England Journal of Medicine · 2023Checked 2026-07-23

Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial

Open record
33
Randomized trialPubMed · Nature Medicine · 2024Checked 2026-07-23

Retatrutide for metabolic dysfunction-associated steatotic liver disease

Open record
38
ReferenceEli Lilly and Company · 2026Checked 2026-07-24

TRIUMPH-2 and TRIUMPH-3 topline results

Open record
40
RegulatoryU.S. Food and Drug Administration · 2026Checked 2026-07-24

FDA concerns with unapproved GLP-1 drugs used for weight loss

Open record
41
Drug labelU.S. Food and Drug Administration · 2024Checked 2026-07-23

EGRIFTA SV (tesamorelin) prescribing information

Open record
42
Drug labelU.S. Food and Drug Administration · 2025Checked 2026-07-23

EGRIFTA WR (tesamorelin) prescribing information

Open record
43
Randomized trialPubMed · Journal of Acquired Immune Deficiency Syndromes · 2010Checked 2026-07-23

Tesamorelin in HIV-associated abdominal fat accumulation

Open record
44
FDA reviewU.S. Food and Drug Administration · 1991Checked 2026-07-23

Geref (sermorelin acetate) approval package

Used bySermorelin
Open record
45
RegulatoryFederal Register · U.S. Food and Drug Administration · 2013Checked 2026-07-23

FDA determination that Geref was not withdrawn for safety or effectiveness

Used bySermorelin
Open record
46
Science reviewPubMed · BioDrugs · 1997Checked 2026-07-23

Sermorelin in diagnosis and treatment of pediatric growth hormone deficiency

Used bySermorelin
Open record
47
FDA reviewU.S. Food and Drug Administration · 2026Checked 2026-07-23

FDA briefing document for TB-500-related bulk drug substances

Used byTB-500
Open record
48
ReferenceU.S. Food and Drug Administration Global Substance Registration System · 2026Checked 2026-07-23

TB-500 substance record

Used byTB-500
Open record
49
Randomized trialPubMed · Archives of Facial Plastic Surgery · 2006Checked 2026-07-23

Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin

Used byGHK-Cu
Open record
50
RegulatoryU.S. Food and Drug Administration · 2026Checked 2026-07-23

503A bulk drug substances under evaluation

Used byGHK-Cu
Open record
51
FDA reviewU.S. Food and Drug Administration · 2026Checked 2026-07-23

FDA briefing document for MOTS-c-related bulk drug substances

Used byMOTS-c
Open record
52
ReferenceU.S. Food and Drug Administration Global Substance Registration System · 2026Checked 2026-07-23

MOTS-c substance record

Used byMOTS-c
Open record
53
FDA reviewU.S. Food and Drug Administration · 2024Checked 2026-07-23

FDA briefing document for AOD-9604-related bulk drug substances

Used byAOD-9604
Open record
54
RegulatoryU.S. Food and Drug Administration · 2021Checked 2026-07-23

Sterile compounded AOD-9604 recall for lack of sterility assurance

Used byAOD-9604
Open record
55
FDA reviewU.S. Food and Drug Administration · 2026Checked 2026-07-23

FDA briefing document for epitalon-related bulk drug substances

Used byEpitalon
Open record
56
PreclinicalPubMed · Biogerontology · 2025Checked 2026-07-23

Epitalon and telomere length in human cell lines

Used byEpitalon
Open record
57
RegulatoryU.S. Food and Drug Administration · 2026Checked 2026-07-23

July 2026 Pharmacy Compounding Advisory Committee meeting

Used byEpitalon
Open record
58
Drug labelU.S. Food and Drug Administration · 2020Checked 2026-07-23

VYLEESI (bremelanotide) prescribing information

Open record
59
Randomized trialPubMed · Obstetrics & Gynecology · 2019Checked 2026-07-23

Bremelanotide for HSDD: two randomized phase 3 trials

Open record
61
Drug labelU.S. Food and Drug Administration · 2024Checked 2026-07-23

SCENESSE (afamelanotide) prescribing information

Open record
62
Randomized trialPubMed · New England Journal of Medicine · 2015Checked 2026-07-23

Afamelanotide for erythropoietic protoporphyria

Open record
63
RegulatoryU.S. Food and Drug Administration · 2019Checked 2026-07-23

Afamelanotide orphan drug designation and approval

Open record
64
Drug labelU.S. Food and Drug Administration · 2024Checked 2026-07-23

FORTEO (teriparatide) prescribing information

Open record
65
Randomized trialPubMed · New England Journal of Medicine · 2001Checked 2026-07-23

Parathyroid hormone for postmenopausal osteoporosis

Open record
66
Randomized trialPubMed · Clinical Orthopaedics and Related Research · 2016Checked 2026-07-23

Teriparatide and femoral-neck fracture healing

Open record
67
Drug labelU.S. Food and Drug Administration · 2025Checked 2026-07-23

TYMLOS (abaloparatide) prescribing information

Open record
68
Randomized trialPubMed · JAMA · 2016Checked 2026-07-23

Abaloparatide vs placebo on new vertebral fractures: ACTIVE

Open record
69
Drug labelU.S. Food and Drug Administration · 2025Checked 2026-07-23

GATTEX (teduglutide) prescribing information

Open record
70
Randomized trialPubMed · Gastroenterology · 2012Checked 2026-07-23

Teduglutide reduces parenteral support in short bowel syndrome

Open record
71
RegulatoryU.S. Food and Drug Administration · 2019Checked 2026-07-23

Teduglutide orphan drug designation and approval

Open record

A transparent trail

One shared source can inform more than one brief.

The index deduplicates identical URLs, then shows every brief that uses the record. A source appearing here means we reviewed and cited it, not that it supports every claim about that peptide.